COVID-19 and tuberculosis-threats and opportunities

Affiliations

• ¹ Center for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital Campus, London, UK.
• ² Marie Bashir Institute for Emerging Infectious Diseases and Biosecurity, University of Sydney, Sydney NSW, Australia.
• ³ Immunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal, I Med Clinic, University of Mainz, Mainz, Germany.
• ⁴ Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
• ⁵ Zambia National Public Health Institute, Ministry of Health, Lusaka, Zambia.
• ⁶ Foundation Congolaise pour la Recherche Médicale/University Marien Ngouabi Brazzaville, Congo, Institute for Tropical Medicine/University of Tübingen, Germany.
• ⁷ Ministry of Health, Lusaka, Zambia.
• ⁸ National Institute of Medical Research, Dar es Salaam, Tanzania.
• ⁹ Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Varese.
• ¹⁰ Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
• ¹¹ Institute for Clinical Medicine, Faculty of Health Sciences, University of Aarhus, Denmark, Department of Melecular Medicine, University of Pavia, Italy.
• ¹² Department of Medicine & Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China.
• ¹³ Lazzaro Spallanzani, National Institute for Infectious Diseases IRCCS, Rome, Italy.
• ¹⁴ Hong Kong Tuberculosis, Chest and Heart Diseases Association, Hong Kong, China.
• ¹⁵ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK, <email></email>, Email: simon.tiberi@nhs.net.